GMP Corrective/Preventative Plans Will Get More FDA Attention – Baxter
FDA's risk-based GMP initiative will require drug manufacturers to become more attentive to corrective and preventative action programs, Baxter Global Regulatory Affairs Director Lisa Skeens, PhD, said
You may also be interested in...
FDA's dispute resolution draft guidance will allow manufacturers 10 days to challenge FDA inspection findings
FDA is planning to train a total of 50 investigators for its pharmaceutical inspectorate program by the end of fiscal year 2007
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011